Clinical development of VEGF trap

Angiogenesis: An Integrative Approach From Science to Medicine

Volumn , Issue , 2008, Pages 415-420

  Rudge, John S ^a   Ioffe, Ella ^a   Cao, Jingtai ^a   Papadopoulos, Nick ^a   Thurston, Gavin ^a   Wiegand, Stanley J ^a   Yancopoulos, George D ^a  

^a REGENERON PHARMACEUTICALS INC   (United States)

Author keywords

kinase inhibitors; vascular eye disease; VEGF Trap

Indexed keywords

EID: 84885766208     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-71518-6_36     Document Type: Chapter

References (65)

1. Folkman J, Klagsbrun M. Angiogenic factors. Science 1987;235(4787):442-7.
2. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005;438(7070):932-6.
3. Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 2002;29(6 Suppl 16):10
4. Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 2005;333(2):328-35.
5. Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with met-astatic renal cell carcinoma. J Clin Oncol 2006;24(16):2505-12.
6. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356(2):125-34.
7. Motzer RJ, Hoosen S, Bello CL, Christensen JG. Sunitinib malate for the treatment of solid tumours: a review of current clinical data. Expert Opin Investig Drugs 2006;15(5):553-61.
8. Ho QT, Kuo CJ. Vascular endothelial growth factor: Biology and therapeutic applications. Int J Biochem Cell Biol 2007.
9. Dvorak HF. Vascular permeability factor/vascular endothe-lial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002;20(21):4368-80.
10. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9(6):669-76.
11. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000;407(6801):242-8.
12. Tischer E, Mitchell R, Hartman T, et al. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 1991;266(18):11947-54.
13. Park JE, Keller GA, Ferrara N. The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the sub-epithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell 1993;4(12):1317-26.
14. Houck KA, Leung DW, Rowland AM, Winer J, Ferrara N. Dual regulation of vascular endothelial growth factor bioavail-ability by genetic and proteolytic mechanisms. J Biol Chem 1992;267(36):26031-7.
15. Keyt BA, Berleau LT, Nguyen H V, et al. The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency. J Biol Chem 1996;271(13):7788-95.
16. Lee S, Jilani SM, Nikolova GV, Carpizo D, Iruela-Arispe ML. Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol 2005;169(4):681-91.
17. Barleon B, Sozzani S, Zhou D, Weich HA, Mantovani A, Marme D. Migration of human monocytes in response to vascular endo-thelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 1996;87(8):3336-43.
18. Clauss M, Gerlach M, Gerlach H, et al. Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med 1990;172(6):1535-45.
19. Gerber HP, Malik AK, Solar GP, et al. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 2002;417(6892):954-8.
20. Shalaby F, Rossant J, Yamaguchi TP, et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 1995;376(6535):62-6.
21. de Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, Williams LT. The fms-like tyrosine kinase, a receptor for vascular endothe-lial growth factor. Science 1992;255(5047):989-91.
22. Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 1998;92(6):735-45.
23. Yoshiji H, Gomez DE, Shibuya M, Thorgeirsson UP. Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer. Cancer Res 1996;56(9):2013-6.
24. Sowter HM, Corps AN, Evans AL, Clark DE, Charnock-Jones DS, Smith SK. Expression and localization of the vascular endo-thelial growth factor family in ovarian epithelial tumors. Lab Invest 1997;77(6):607-14.
25. Volm M, Koomagi R, Mattern J. Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer. Int J Cancer 1997;74(1):64-8.
26. Ellis LM, Takahashi Y, Fenoglio CJ, Cleary KR, Bucana CD, Evans DB. Vessel counts and vascular endothelial growth factor expression in pancreatic adenocarcinoma. Eur J Cancer 1998;34(3):337-40.
27. Tomisawa M, Tokunaga T, Oshika Y, et al. Expression pattern of vascular endothelial growth factor isoform is closely correlated with tumour stage and vascularisation in renal cell carcinoma. Eur J Cancer 1999;35(1):133-7.
28. Iliopoulos O, Levy AP, Jiang C, Kaelin WG, Jr., Goldberg MA. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci USA 1996;93(20):10595-9.
29. Lonser RR, Glenn GM, Walther M, et al. von Hippel-Lindau disease. Lancet 2003;361(9374):2059-67.
30. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993;362(6423):841-4.
31. Prewett M, Huber J, Li Y, et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 1999;59(20):5209-18.
32. Gerber H P, Kowalski J, Sherman D, Eberhard DA, Ferrara N. Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. Cancer Res 2000;60(22):6253-8.
33. Smith JK, Mamoon NM, Duhe RJ. Emerging roles of targeted small molecule protein-tyrosine kinase inhibitors in cancer therapy. Oncol Res 2004;14(4-5):175-225.
34. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002;99(17):11393-8.
35. Rudge JS, Thurston G, Davis S, et al. VEGF trap as a novel anti-angiogenic treatment currently in clinical trials for cancer and eye diseases, and VelociGene-based discovery of the next generation of angiogenesis targets. Cold Spring Harb Symp Quant Biol 2005;70:411-8.
36. Liang WC, Wu X, Peale F V, et al. Cross-species vascular endothe-lial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J Biol Chem 2006;281(2):951-61.
37. Byrne AT, Ross L, Holash J, et al. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res 2003;9(15):5721-8.
38. Wachsberger PR, Burd R, Cardi C, et al. VEGF Trap in combination with radiotherapy improves tumor control in U87 glioblas-toma. Int J Radiat Oncol Biol Phys 2007.
39. Shaheen RM, Ahmad SA, Liu W, et al. Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors. Br J Cancer 2001;85(4): 584-9.
40. Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006;3(1):24-40.
41. Massarelli E, Miller VA, Leighl N, et al. Phase II Study of the Efficacy and Safety of Intravenous (IV) AVE0005 (VEGF Trap) Given Every 2 Weeks in Patients (Pts) with Platinum-and Erlotinib-Resistant Adenocarcinoma of the Lung (NSCLA). ASCO Abs 2007.
42. Tew WP, Colombo N, Ray-Coquard I, et al. VEGF-Trap for patients (pts) with recurrent platinum-resistant epithelial ovarian cancer (EOC): Preliminary results of a randomized, multicenter phase III study. ASCO Abs 2007;In Press.
43. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350(23):2335-42.
44. Yang JC. Bevacizumab for patients with metastatic renal cancer: an update. Clin Cancer Res 2004;10(18 Pt 2):6367S-70S.
45. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bev-acizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349(5):427-34.
46. Luttun A, Tiwa M, Carmeliet P. Placental growth factor (PlGF) and its receptor Flt-1 (VEGFR1): novel therapeutic targets for angiogenic disorders. Ann NY Acad Sci 2002;979:80-93.
47. Fukasawa M, Korc M. Vascular endothelial growth factor-trap suppresses tumorigenicity of multiple pancreatic cancer cell lines. Clin Cancer Res 2004;10(10):3327-32.
48. Huang J, Frischer JS, Serur A, et al. Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Proc Natl Acad Sci USA 2003;100(13):7785-90.
49. Dalal S, Berry AM, Cullinane CJ, et al. Vascular endothelial growth factor: a therapeutic target for tumors of the Ewing's sarcoma family. Clin Cancer Res 2005;11(6):2364-78.
50. Hu L, Hofmann J, Holash J, Yancopoulos GD, Sood AK, Jaffe RB. Vascular endothelial growth factor trap combined with pacl-itaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model. Clin Cancer Res 2005;11(19 Pt 1):6966-71.
51. Rudge JS, Holash J, Hylton D, et al. VEGF Trap Complex Formation measures production rates of VEGF, providing a new biomarker for predicting efficacious angiogenic blockade. PNAS 2007; Proc Natl Acad Sci USA 2007;104(47):18363-70.
52. Aiello LM, Cavallerano J. Diabetic retinopathy. Curr Ther Endo-crinol Metab 1994;5:436-46.
53. Malecaze F, Clamens S, Simorre-Pinatel V, et al. Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy. Arch Ophthalmol 1994;112(11):1476-82.
54. Congdon N, O'Colmain B, Klaver CC, et al. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 2004;122(4):477-85.
55. Saishin Y, Saishin Y, Takahashi K, et al. VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. J Cell Physiol 2003;195(2):241-8.
56. Wiegand S, Cao J, Renard R, Rudge J, Yancopoulos G. Long-lasting inhibition of corneal neovascularization following systemic administration of the VEGF Trap. Invest Ophthalmol Vis Sci 2003;44(Abstract):829.
57. Qaum T, Xu Q, Joussen AM, et al. VEGF-initiated blood-retinal barrier breakdown in early diabetes. Invest Ophthalmol Vis Sci 2001;42(10):2408-13.
58. Cursiefen C, Cao J, Chen L, et al. Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. Invest Ophthal-mol Vis Sci 2004;45(8):2666-73.
59. Wiegand SJ, Zimmer E, Nork TM, et al. VEGF Trap Both Prevents Experimental Choroidal Neovascularization and Causes Regression of Established Lesions in Non-Human Primates. Invest Ophthalmol Vis Sci 2005;46:E-Abstract 1411.
60. Ciulla TA. VEGF Trap, Potential Therapeutic Role for Neovas-cular AMD and DME. ARVO 2007.
61. Benzl MS, Nguyen QD, Chu K, et al. CLEAR-IT-2: Interim Results Of The Phase II, Randomized, Controlled Dose-and Interval-ranging Study Of Repeated Intravitreal VEGF Trap Administration In Patients With Neovascular Age-related Macu-lar Degeneration (AMD). 2007.
62. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355(14):1432- 44.
63. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355(14):1419-31.
64. Rosenfeld PJ, Rich RM, Lalwani GA. Ranibizumab: Phase III clinical trial results. Ophthalmol Clin North Am 2006;19(3):361-72.
65. Dol DV, Nguyen QD, Browning DJ, et al. An Exploratory Study of the Safety, Tolerability and Biological Effect of a Single Intra-vitreal Administration of VEGF Trap in Patients with Diabetic Macular Edema ARVO 2007.